参芪扶正注射液联合化疗治疗卵巢癌疗效及对免疫功能和肿瘤标记物的影响  

Efficacy of Shenqi Fuzheng Injection Combined with Chemotherapy in Treatment of Ovarian Cancer and Its Influence on Immune Function and Tumor Markers

作　　者：诸一鸣[1] 陈平[2] 郑爱文[1] ZHU Yiming;CHEN Ping;ZHENG Aiwen(Department of Gynecology, Zhejiang Tumor Hospital, Hangzhou 310022,Zhejiang,China;Anesthesiology , Zhejiang Tumor Hospital, Hangzhou 310022, Zhejiang, China)

机构地区：[1]浙江省肿瘤医院妇瘤科,浙江杭州310022 [2]浙江省肿瘤医院麻醉科,浙江杭州310022

出　　处：《中华中医药学刊》2018年第2期479-482,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省医药卫生科研基金项目(2017KY248)

摘　　要：目的：探讨参芪扶正注射液联合化疗治疗卵巢癌患者疗效观察及对患者免疫功能和肿瘤标记物的影响。方法：选自医院于2012年1月—2017年1月期间收治的卵巢癌患者100例,按照随机表法分为观察组50例与对照组50例。观察组采用参芪扶正注射液联合化疗治疗,对照组仅采用化疗治疗。两组均以21 d为1个周期,连续治疗3个周期判定疗效。比较两组近期疗效、生活质量改善情况,治疗前后T淋巴细胞亚群、肿瘤标记物变化,及不良反应情况。结果：观察组总有效率（62.00%）高于对照组（38.00%）（P〈0.05）;观察组生活质量改善率（68.00%）高于对照组（42.00%）（P〈0.05）;两组治疗后CD_3~＋、CD_4~＋和CD_4~＋/CD_8~＋增加（观察组：t=9.7588、11.736 8、7.214 5,对照组：t=7.395 6、6.571 6、6.135 6,P〈0.05）;观察组治疗后CD_3~＋、CD_4~＋和CD_4~＋/CD_8~＋高于对照组（t=15.541 8、16.551 8、12.652 8,P〈0.05）;两组治疗后CA199、CEA和CA125水平降低（观察组：t=42.139 8、17.407 8、25.044 2,对照组：t=16.622 2、8.538 8、11.820 8,P〈0.05）;观察组治疗后CA199、CEA和CA125水平低于对照组（t=28.325 8、10.713 5、13.722 0,P〈0.05）;观察组血小板减少、白细胞减少、胃肠道反应、骨髓抑制及脱发发生率低于对照组（P〈0.05）。结论：参芪扶正注射液联合化疗治疗卵巢癌患者疗效明显,可增强患者免疫功能,降低血清肿瘤标志物CA199、CEA和CA125水平,且不良反应小,具有重要研究意义。Objective：To investigate the effect of Shenqi Fuzheng Injection combined with chemotherapy on ovarian cancer and its influence on immune function and tumor markers. Methods ： A total of 100 cases of ovarian cancer treated in our hospital from January 2012 to January 2017 were randomly divided into the observation group （50 cases） and the control group （50 cases）. The observation group was treated by Shenqi Fuzheng Injection combined with chemotherapy, while the control group was treated with chemotherapy only. The two groups were treated for 21 d as a cycle, continuous treatment for 3 cycles and then we determined the efficacy. The short - term efficacy and quality of life in the two groups were compared, and the changes of T lymphocyte subsets, tumor markers and side effects were observed before and after treatment. Results ： The total effective rate of the observation group （62.00%） was higher than that of the control group （ 38.00% ） （ P 〈 0.05 ）. The improvement rate of quality of life in observation group （ 68.00% ） was higher than that in the control group （42.00%） （P 〈0. 05）. The CD3＋ , CD4 and CD4/CD8 increased after treatment in the two groups （ observation group ： t = 9. 758 8, 11. 736 8, 7. 214 5, control group ： t=7. 395 6, 6. 571 6, 6. 135 6, P 〈 0. 05）. The CD3＋ , CD4 and CD4/CDs in the observation group after treatment were higher than those in the control group （t = 15. 541 8, 16. 551 8, 12. 652 8, P 〈0. 05）. The levels of CA199, CEA and CA125 were decreased in the two groups after treatment （observation group： t = 42. 139 8, 17. 407 8, 25. 044 2, control group： t = 16. 622 2, 8. 538 8, 11. 820 8 ,P 〈0. 05）. After treatment, the levels of CA199, CEA and CA125 in the observation group were lower than those in the control group （t = 28. 325 8, 10. 713 5, 13. 722 0, P 〈 0. 05）. The incidence of thromboeytopenia, leuko-cyte reduction, gastrointestinal reaction, myelosuppression and alopecia in the observation group were lowe

关 键 词：参芪扶正注射液 化疗 卵巢癌 疗效 免疫功能 肿瘤标记物 

分 类 号：R737.31[医药卫生—肿瘤]